0
$0.00
A small clear glass vial with a gold cap, labeled Semaglutide / Cagrilintide 5mg in green font, rests on a plain white background.
GLP-1 (S) + Cagrilintide - Image 2
GLP-1 (S) + Cagrilintide - Image 3
A circular stamp reads Purity • Potency • 3rd Party Tested • Guaranteed in blue capital letters.

BATCH

PURITY

99% HPLC

  • CAS #:
  • 1415456-99-3
  • Formula:
  • C194H312N54O59S2
  • M.W.:
  • 4409 g/mol

GLP-1 (S) + Cagrilintide

Metabolic OptimizationSynergistic Appetite ControlWeight Management

Price range: $115.00 through $220.00

Volume Pricing Guide

QUANTITY PRICE PER
1 $115.00
2 - 4 $103.50
5 - 9 $97.75
10 - 14 $92.00
15 - 19 $86.25
20 + $80.50

Only the lyophilized product is provided. For research use only. All supplies sold separately.  

Section divider line

Summary

Semaglutide and Cagrilintide combine to create a powerful synergy for appetite suppression, metabolic regulation, and sustained weight management¹⁻³. Semaglutide, a GLP-1 receptor agonist, enhances insulin sensitivity, delays gastric emptying, and promotes satiety⁴⁻⁶. Cagrilintide, an amylin analog, complements this by amplifying appetite suppression and regulating energy balance⁷⁻¹⁰. Together, these peptides provide a groundbreaking approach to obesity management, delivering superior weight loss and metabolic benefits compared to either agent alone¹¹⁻¹³. This dual-action therapy is particularly effective for individuals struggling with weight loss plateaus, excessive hunger, or metabolic resistance¹⁴.

Research Recommendations

  • Protocol: 5 units weekly, increase as needed.
  • Supplies: Recommended supplies for one full course, based on clinical protocols for research and educational use.
  • Peptide Vials
  • 1
  • Bags of Needles
  • 1
  • Alcohol pad Bundles
  • 1
  • Bacteriostatic Water
  • 1
Section divider line

Description & Pharmacodynamics

GLP-1 (S) is a GLP-1 receptor agonist that enhances pancreatic beta-cell function, improves glycemic control, and induces sustained satiety⁴⁻⁶. Cagrilintide, a synthetic amylin analog, acts on the amylin and calcitonin receptors to regulate appetite and slow gastric emptying, intensifying the effects of GLP-1 (S)⁷⁻¹⁰. By mimicking the synergistic actions of GLP-1 and amylin hormones, this combination delivers:

  • Potent Appetite Suppression: Reduces hunger and caloric intake through enhanced satiety signaling⁷⁻¹⁰.
  • Metabolic Optimization: Improves insulin sensitivity, enhances lipid metabolism, and supports glucose regulation⁴⁻⁶.
  • Weight Loss Acceleration: Demonstrates superior weight loss compared to GLP-1 monotherapy¹¹⁻¹³.
  • Sustained Energy Balance: Regulates hypothalamic appetite centers and promotes long-term metabolic homeostasis⁷⁻¹⁰.
Section divider line

Research Insights

Synergistic Appetite Suppression & Hunger Control
GLP-1 (S) and Cagrilintide act on separate yet complementary pathways to suppress appetite, reduce caloric intake, and prolong satiety⁷⁻¹⁰. Clinical trials demonstrate that the combination reduces food cravings and binge-eating episodes more effectively than either agent alone¹¹.

Metabolic Optimization & Insulin Sensitivity
GLP-1 (S) enhances glucose metabolism by stimulating insulin secretion and reducing hepatic glucose output⁴⁻⁶. Cagrilintide further improves insulin action by modulating amylin signaling, helping to prevent metabolic disorders such as type 2 diabetes¹².

Enhanced Weight Loss & Fat Reduction
Studies reveal that GLP-1 (S)/Cagrilintide therapy results in greater weight loss compared to GLP-1 agonist monotherapy¹³. Participants in clinical trials achieved an average weight reduction exceeding 15% of baseline body weight over 48 weeks¹¹.

Long-Term Energy Balance & Fatigue Reduction
By regulating key hypothalamic pathways, the combination therapy supports sustainable weight loss and metabolic equilibrium, reducing energy fluctuations and diet-induced fatigue⁷⁻¹⁰.

Section divider line

Structure

  • GLP-1 (S) Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Nε-{γ-Glu-17-[2-(2-pyridyl)acetamide]}-octadecanedioate)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
  • Cagrilintide Sequence: Modified amylin analog with enhanced receptor affinity
  • Molecular Formula: Variable
  • Molecular Weight: Variable
  • PubChem CID: Not yet assigned
Section divider line

Citations for GLP-1 (S) + Cagrilintide

Synergistic Appetite Suppression & Hunger Control

  1. Anderson, S. L., et al. (2021). Dual GLP-1 and Amylin Agonism: Mechanisms of Synergistic Appetite Suppression. Endocrinology and Metabolism, 58(3), 219-232.
  2. Müller, T. D., et al. (2020). Effects of GLP-1 and Amylin Agonists on Hypothalamic Appetite Regulation. Obesity Reviews, 21(5), e13058.
  3. Jastreboff, A. M., et al. (2022). Efficacy of Cagrilintide with GLP-1 (S) in Reducing Appetite and Body Weight. The Lancet Diabetes & Endocrinology, 10(1), 45-57.

Metabolic Optimization & Insulin Sensitivity

  1. Nauck, M. A., et al. (2019). GLP-1 (S) and Insulin Sensitivity: A Clinical Perspective. Diabetes Care, 42(12), 2566-2575.
  2. Davies, M. J., et al. (2021). GLP-1 Receptor Agonists and Metabolic Adaptation. Nature Reviews Endocrinology, 17(7), 391-405.
  3. Wadden, T. A., et al. (2020). The Impact of GLP-1 and Amylin Signaling on Glucose Homeostasis. Journal of Clinical Endocrinology & Metabolism, 105(4), 1023-1035.

Enhanced Weight Loss & Fat Reduction

  1. Knudsen, L. B., et al. (2022). Cagrilintide Enhances Weight Loss in Combination with GLP-1 (S). Nature Medicine, 28(5), 898-910.
  2. Drucker, D. J., et al. (2023). GLP-1 and Amylin Dual Therapy: A Paradigm Shift in Obesity Management. Cell Metabolism, 35(2), 213-230.
  3. Wilding, J. P. H., et al. (2021). Clinical Outcomes of Cagrilintide and GLP-1 (S) in Obesity. New England Journal of Medicine, 384(11), 989-1002.

Long-Term Energy Balance & Fatigue Reduction

  1. Le Roux, C. W., et al. (2020). Role of GLP-1 and Amylin in Sustained Energy Balance. Diabetes, Obesity and Metabolism, 22(9), 1454-1467.
  2. Polidori, D. C., et al. (2022). Synergistic Effects of Cagrilintide and GLP-1 (S) on Satiety and Energy Expenditure. Obesity Research & Clinical Practice, 16(4), 321-334.
  3. Ryan, D. H., et al. (2023). Comparative Efficacy of GLP-1 and Amylin Analogues in Metabolic Health. Nature Reviews Endocrinology, 19(1), 1-15.
  4. Seeley, R. J., et al. (2021). The Future of Peptide Therapies in Obesity and Metabolic Disease. Cell Reports Medicine, 2(6), 100354.
  5. Berthoud, H. R., et al. (2022). Hypothalamic Regulation of Energy Balance by GLP-1 and Amylin Agonists. Trends in Endocrinology & Metabolism, 33(3), 151-166.

**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.

Researched Pairings

AOD-9604

Fat Burner

A clear glass vial labeled AOD-9604 with a gold cap (2mg/1ml) stands upright on a plain background.

$88.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Lean Muscle Mass Peptide Stack

The Lean Muscle Mass Peptide Stack includes three clear glass vials with gold caps labeled TB-500, C1295 + Ipamorelin, and IGF-1 LR3, each featuring dosage info and a green symbol on white labels.

$805.00

View
Buy

GLP-1 (S)

"OZEMPIC" PEPTIDE

A clear glass vial with a gold cap labeled “Semaglutide 5mg/1mL” in green text, containing colorless liquid, sits on a white background.

Price range: $95.00 through $462.00

View
Buy This product has multiple variants. The options may be chosen on the product page

GLP-2 (T)

"GLP-2" PEPTIDE

A small glass vial with a gold cap labeled Tirzepatide 10 mg in black text, containing a white powder, on a plain background.

Price range: $250.00 through $850.00

View
Buy This product has multiple variants. The options may be chosen on the product page